Related Experiment Video
Updated: Apr 6, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease: A Retrospective Study of 10
Maxime Dauvergne1, Anissa Moktefi, Marion Rabant
1From the Service de Néphrologie et Transplantation (MD, TK, TS, PR, PG, PL, DS, VA), Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Centre de référence maladie rare Syndrome Néphrotique Idiopathique, Institut Francilien de recherche en Néphrologie et Transplantation (IFRNT), DHU VIC (Virus-Immunité-Cancer), AP-HP (Assistance Publique-Hôpitaux de Paris), Université Paris Est Créteil (UPEC), Créteil, France; Equipe 21 (MD, AM, TK, TS, DD, PG, PL, DS, VA), INSERM Unité 955, Université Paris Est Créteil, Créteil, France; Département de Pathologie (AM, DD), Groupe Hospitalier Henri-Mondor/Albert-Chenevier, AP-HP, UPEC, Créteil, France; Service d'Anatomie pathologique (MR), Hôpital Necker - Enfants Malades, AP-HP, Université Paris Descartes, Paris, France; CHU Pontchaillou (CV, TF), Service de Néphrologie, Université de Rennes, Rennes, France; Service de Néphrologie et de Transplantation Rénale (SB), Hôpital de la Conception, AP-HM, Aix-Marseille Université, Marseille, France; Centre de Référence Maladies Rares des Maladies Inflammatoires des Voies Biliaires & Service d'Hépatologie (CC, OC), Hôpital Saint-Antoine, Centre de Référence Maladies Rares des Maladies Inflammatoires des Voies Biliaires & Service d'Hépatologie; Inserm, UMR-S 938, Centre de Recherche Saint-Antoine; AP-HP, Sorbonne Universités, Université Pierre et Marie Curie (UPMC), Paris, France; CHU Pontchaillou (N R-L), Service d'Anatomie Pathologie, Université de Rennes, Rennes, France; Service d'Anatomie pathologique (PR), Hôpital de la Pitié-Salpétrière, AP-HP, UPMC, Paris, France; Service de Néphrologie et Dialyse (BK), Hôpital Necker-Enfants Malades, AP-HP, Université Paris Descartes, Paris, France; Service de Néphrologie et Dialyses (J-J B, KD), Hôpital Tenon, AP-HP, UMPC, Paris, France; Service de Néphrologie (ED, MJ), Groupe hospitalier Bichat/Claude-Bernard, AP-HP, Université Paris Diderot, Paris, France; Service d'Anatomie pathologique (IB), Hôpital Tenon, AP-HP, UPMC, Paris, France.
Abstract:
The association between membranous nephropathy (MN) and immunological disorder-related liver disease has not been extensively investigated, and the specific features of this uncommon association, if any, remain to be determined.We retrospectively identified 10 patients with this association. We aimed to describe the clinical, biological, and pathological characteristics of these patients and their therapeutic management. The possible involvement of the phospholipase A2 receptor (PLA2R) in these apparent secondary forms of MN was assessed by immunohistochemistry with renal and liver biopsy specimens.The mean delay between MN and liver disease diagnoses was 3.9 years and the interval between the diagnosis of the glomerular and liver diseases was <1.5 years in 5 patients. MN was associated with a broad spectrum of liver diseases including primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH), and primary sclerosing cholangitis (PSC). AIH whether isolated (n = 3) or associated with PBC (n = 2) or PSC (n = 2) was the most frequent autoimmune liver disease. Circulating PLA2R antibodies were detected in 4 out of 9 patients but the test was performed under specific immunosuppressive treatment in 3 out of 9 patients. Seven of the 9 patients with available renal tissue specimens displayed enhanced expression of PLA2R in glomeruli whereas PLA2R was not expressed in liver parenchyma from these patients or in normal liver tissue. The study of immunoglobulin (Ig) subclasses of deposits in glomeruli revealed that the most frequent pattern was the coexistence of IgG1 and IgG4 immune deposits with IgG4 predominating.Detection of PLA2R antibodies in glomeruli but not in liver parenchyma is a common finding in patients with MN associated with autoimmune liver disease, suggesting that these autoantibodies are not exclusively detected in idiopathic MN.
Insights
Membranous nephropathy (MN) can occur with autoimmune liver diseases. Phospholipase A2 receptor (PLA2R) antibodies were found in kidney tissue, not liver, suggesting MN isn't always idiopathic.
Area of Science:
- Nephrology
- Hepatology
- Immunology
Background:
- The link between membranous nephropathy (MN) and autoimmune liver diseases is poorly understood.
- Specific clinical, biological, and pathological features of this association require further investigation.
Purpose of the Study:
- To characterize patients with co-occurring MN and autoimmune liver disease.
- To investigate the role of phospholipase A2 receptor (PLA2R) in these cases.
Main Methods:
- Retrospective analysis of 10 patients with MN and autoimmune liver disease.
- Immunohistochemistry on renal and liver biopsy specimens to detect PLA2R.
- Analysis of immunoglobulin (Ig) subclass deposits in glomeruli.
Main Results:
- Autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) were associated liver diseases.
- PLA2R expression was enhanced in glomeruli but absent in liver parenchyma.
- Coexistence of IgG1 and IgG4 deposits, predominantly IgG4, was common in glomeruli.
Conclusions:
- PLA2R antibodies in glomeruli, but not liver, are common in MN associated with autoimmune liver disease.
- This suggests PLA2R-related MN may occur secondary to autoimmune liver conditions, not exclusively idiopathic MN.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Nephrotic Syndrome II : Assessment and Medical Management
Nephrons
Chronic Kidney Disease II: Clinical Manifestations
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

